Vishal Deshmukh, Scripps Institute to accept award for excellence in the application of high content technology in Multiple Sclerosis research
PITTSBURGH, PA (February 18, 2014) – Thermo Fisher Scientific, the world leader in serving science, this week will present its 2014 Cellome Award to the authors of the peer-reviewed article, “A regenerative approach to the treatment of multiple sclerosis,” that was featured in the October 2013 issue of Nature. Vishal Deshmukh, of The Scripps Research Institute will be accepting the award on behalf of all the contributing authors of the paper during the Cambridge Healthtech Institute’s High Content Analysis Meeting, February 19-20, 2014 in La Jolla, CA. Contributing to the paper’s selection was the use of high content technology and its potential clinical impact by showing the effectiveness of benztropine administration alone or in conjunctive therapy in a Multiple Sclerosis model to enhance remyelination and functional recovery.
The Thermo Scientific Cellome Award is presented annually by Thermo Fisher Scientific’s cellular imaging and analysis business to the authors of the most impactful peer-reviewed article which showcases high content technology as a fundamental method. Papers using Thermo Scientific cellular imaging and analysis products are collected and reviewed throughout the year, and one paper is selected which represents the best use of high content technology in life science research.
“We congratulate Vishal and his team on receiving this year’s award,” said Audra Ziegenfuss, technical product manager, cellular imaging and analysis, Thermo Fisher. “This in vivo evidence contributes to the development of novel therapies in the treatment of multiple sclerosis and ultimately improved clinical management of this patient population.” “I have taken a phenotypic rather than target based approach using various readouts, including high-throughput high content imaging,” said Deshmukh. “I am extremely happy to receive this award as recognition of our HCI-HTS efforts and hope to continue using this approach in various other assays."
Contributors to the Nature paper include: Vishal A. Deshmukh, Virginie Tardif, Costas A. Lyssiotis, Chelsea C. Green, Bilal Kerman, Hyung Joon Kim, Krishnan Padmanabhan, Jonathan G. Swoboda, Insha Ahmad, Toru Kondo, Fred H. Gage, Argyrios N. Theofilopoulos, Brian R. Lawson, Peter G. Schultz, and Luke L. Lairson.
For more information on the Thermo Scientific cell imaging and analysis product family, visit www.thermoscientific.com/highcontent.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $17 billion and 50,000 employees in 50 countries. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Our four premier brands – Thermo Scientific, Life Technologies, Fisher Scientific and Unity Lab Services – offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.